Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

NSF awards Georgia Institute of Technology $3 million for stem cell bio-manufacturing research program

The National Science Foundation (NSF) has awarded $3 million to the Georgia Institute of Technology to fund a unique research program on stem cell bio-manufacturing. The program is specifically focused on developing engineering methods for stem cell production, in order to meet the anticipated demand for stem cells. The award comes through the NSF's Integrative Graduate Education and Research Traineeship (IGERT) Program, which supports innovation in graduate education in fields that cross academic disciplines and have broad societal impact.

17 Aug 2010

Human induced pluripotent stem cells help to treat Parkinson’s disease: Research

Researchers at the Buck Institute for Age Research have successfully used human induced pluripotent stem cells (iPSCs) to treat rodents afflicted with Parkinson's Disease (PD). The research, which validates a scalable protocol that the same group had previously developed, can be used to manufacture the type of neurons needed to treat the disease and paves the way for the use of iPSC's in various biomedical applications. Results of the research, from the laboratory of Buck faculty Xianmin Zeng, Ph.D., are published August 16, 2010 in the on-line edition of the journal Stem Cells.

17 Aug 2010

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

CEL-SCI reported a net loss for the three months ended June 30, 2010 of ($0.6) million versus a loss of ($6.2) million during the same three months in fiscal year 2009. Net loss per basic share was ($0.00) for the three months ended June 30, 2010 versus a loss per basic share of ($0.05) during the same three months in fiscal year 2009. The loss during the quarter ended June 30, 2010 was reduced by a gain on derivative instruments of $2.75 million.

17 Aug 2010

Cytomedix second quarter 2010 revenue increases 102% to $1.15 million

Cytomedix, Inc. (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced financial results for the three and six months ended June 30, 2010.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

BioPharm second quarter 2010 revenues rise 26%

BioPharm Asia, Inc.,a producer, distributor and retailer of medical products in China, today announced its financial results for the second quarter ended June 30, 2010.

17 Aug 2010

Nutrastar second-quarter revenues increase 63.4% to $5.46 million

Nutrastar International Inc., a leading nutraceutical company which produces and distributes Chinese Golden Grass and other specialty food products, today announced financial results for their three and six months ended June 30, 2010.

16 Aug 2010

Michigan Accelerator Fund 1 launched to support early stage life science and technology companies

Michigan Accelerator Fund I, L.P., today announced the formation of the community's first venture capital fund formed specifically to support early stage life science and technology companies: the Michigan Accelerator Fund 1 (MAF1).

16 Aug 2010

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

Jiangbo Pharmaceuticals, Inc., today announced that the Company received approval from the Shandong Food and Drug Administration to start the sales of Felodipine sustained release tablets.

16 Aug 2010

NeoStem second-quarter revenues increase 26% to $19.4 million

NeoStem, Inc. an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units, U.S. adult stem cells, China adult stem cells, and China pharmaceuticals is today providing results of its second quarter 2010.

16 Aug 2010

PLC Systems second-quarter total revenues decrease to $1,019,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and six month periods ended June 30, 2010.

16 Aug 2010

AMRI selected as inaugural winner of Pfizer Route Design Innovation Award

AMRI announced today that it has been selected as the inaugural winner of the Pfizer Route Design Innovation Award, beating out 40 companies who were invited to share innovative ideas for process chemistry and large scale Active Pharmaceutical Ingredient production. Pfizer will present the company with the award at the AMRI 2010 Integrated Drug Discovery Symposium to be held in Albany NY, October 13-14. AMRI will also receive an honorarium for its win.

16 Aug 2010

Vitacost.com second-quarter net sales increase 14.1% to $54.0 million

Vitacost.com, Inc., a leading online retailer and direct marketer of health and wellness products, today reported financial results for the second quarter ended June 30, 2010.

16 Aug 2010

Green Cross receives KFDA approval to manufacture, market i.v. peramivir: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. announced that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA for intravenous peramivir to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza. Green Cross Corp. intends to launch peramivir under the commercial name PeramiFlu in South Korea.

16 Aug 2010

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and six-month periods ended June 30, 2010.

16 Aug 2010

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of The Transplantation Society, being held August 15-19, 2010, in Vancouver, British Columbia, Canada. In total, 18 abstracts from company-sponsored studies will be presented during the congress.

16 Aug 2010

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

US WorldMeds, LLC, a Kentucky-based specialty pharmaceutical company that develops unique products to address unmet medical needs, today announced it has acquired Solstice Neurosciences, Inc. for $35 million. The acquisition expands US WorldMeds' operations, adds to the company's growing portfolio of products and enhances the company's ability to create and deliver high-quality specialty pharmaceutical products to its targeted global markets.

16 Aug 2010

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Four Mass. hospitals investigate trashing of patient health records, Calif. employers worry about workers using marijuana on job

"Four Massachusetts community hospitals are investigating how thousands of patient health records, some containing Social Security numbers and sensitive medical diagnoses, ended up in a pile at a public dump. The unshredded records included pathology reports with patients' names, addresses, and results of breast, bone, and skin cancer tests, as well as the results of lab work following miscarriages. By law, medical records and documents containing personal identifying information must be disposed of in a way that protects privacy, and leaving them at a dump is probably illegal, privacy lawyers and hospital officials said" (Kowalczyk, 8/13).

13 Aug 2010

Trubion Pharmaceuticals signs definitive merger agreement with Emergent BioSolutions

Trubion Pharmaceuticals, Inc. today announced the signing of a definitive merger agreement with Emergent BioSolutions Inc., in which Emergent has agreed to acquire Trubion. Under the terms of the agreement, each share of Trubion common stock will be converted into the right to receive an upfront payment of $1.365 per share in cash and 0.1641 shares of Emergent BioSolutions common stock.

13 Aug 2010

Manufacturing News and Research

Further Reading

NSF awards Georgia Institute of Technology $3 million for stem cell bio-manufacturing research program

Human induced pluripotent stem cells help to treat Parkinson’s disease: Research

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

Cytomedix second quarter 2010 revenue increases 102% to $1.15 million

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

BioPharm second quarter 2010 revenues rise 26%

Nutrastar second-quarter revenues increase 63.4% to $5.46 million

Michigan Accelerator Fund 1 launched to support early stage life science and technology companies

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

NeoStem second-quarter revenues increase 26% to $19.4 million

PLC Systems second-quarter total revenues decrease to $1,019,000

AMRI selected as inaugural winner of Pfizer Route Design Innovation Award

Vitacost.com second-quarter net sales increase 14.1% to $54.0 million

Green Cross receives KFDA approval to manufacture, market i.v. peramivir: BioCryst Pharmaceuticals

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

New T cell engineering approach can improve success rate of immune-cell therapies

Four Mass. hospitals investigate trashing of patient health records, Calif. employers worry about workers using marijuana on job

Trubion Pharmaceuticals signs definitive merger agreement with Emergent BioSolutions

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News